Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study

NCT01261169 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2010-12-16

No results posted yet for this study

Summary

This study is designed to explore the use of Myfortic® in patients with steroid-refractory uveitis. The aim of the study will be to show the therapeutic effect of Myfortic® in managing uveitis patients.

Conditions

  • Uveitis

Interventions

DRUG

Myfortic

Myfortic in uveitis

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY
  • Genovate Biotechnology Co., Ltd.,

    lead INDUSTRY

Principal Investigators

  • Hwang Yih Shiou, MD · CGMH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Completion
2011-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01261169 on ClinicalTrials.gov